Alzheimer’s research, from previous studies to ongoing clinical trials, is often not representative of the populations that are at the highest risk for this disease. Margaret Pericak-Vance, Ph.D., sits down with Dean Henri Ford to discuss a multi-center, multi-national clinical trial that will tackle this issue and expand diversity in Alzheimer’s data, eventually leading to the development of targeted drug therapies.